<SEC-DOCUMENT>0001808805-23-000079.txt : 20231122
<SEC-HEADER>0001808805-23-000079.hdr.sgml : 20231122
<ACCEPTANCE-DATETIME>20231121183119
ACCESSION NUMBER:		0001808805-23-000079
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20231122
DATE AS OF CHANGE:		20231121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nautilus Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001808805
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				981541723
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258100
		FILM NUMBER:		231429514

	BUSINESS ADDRESS:	
		STREET 1:		2701 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206-333-2001

	MAIL ADDRESS:	
		STREET 1:		2701 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARYA Sciences Acquisition Corp III
		DATE OF NAME CHANGE:	20200408
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>nautilusbiotechnology-pros.htm
<DESCRIPTION>424B3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie2d33a3a968e47c2af31c3732e986f3f_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed pursuant to Rule 424(b)(3) </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registration Statement No. 333-258100 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROSPECTUS SUPPLEMENT </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,738,387 Shares of Common Stock </font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:212px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This prospectus supplement updates and amends the prospectus dated August 8, 2022 (as supplemented to date, the &#8220;Prospectus&#8221;), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333- 258100) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 22, 2021, as amended by Post-Effective Amendment No. 1 to Form S-1 filed with the SEC on February 24, 2022, and Post-Effective Amendment No. 2 to Form S-1 on Form S-3 filed with the SEC on August 2, 2022 and declared effective by the SEC on August 8, 2022 (the &#8220;Registration Statement&#8221;). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Prospectus and this prospectus supplement relate to (i) the resale of 4,286,500 shares of common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) issued in connection with the Domestication (as defined in the Prospectus) by certain of the selling securityholders named in the Prospectus (each a &#8220;selling securityholder&#8221; and, collectively, the &#8220;selling securityholders&#8221;), (ii) the resale of 69,655,827 shares of Common Stock issued in connection with the Business Combination (as defined in the Prospectus) by certain of the selling securityholders, (iii) the resale of 13,093,331 shares of Common Stock issued in the PIPE Financing (as defined in the Prospectus) by certain of the selling securityholders, and (iv) the resale of 1,702,729 shares of Common Stock reserved for issuance upon the exercise of certain outstanding options to purchase Common Stock. We will not receive any proceeds from the sale of our securities offered by the selling securityholders under the Prospectus. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement. This prospectus supplement updates, amends and supplements the information included or incorporated by reference in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Common Stock is listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;NAUT.&#8221; On November 21, 2023, the last quoted sale price for our Common Stock as reported on Nasdaq was $2.70 per share. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">We are an &#8220;emerging growth company,&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in the section titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8221; beginning on page 7 of the Prospectus. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">You should rely only on the information contained in the Prospectus, this prospectus supplement or any prospectus supplement or amendment hereto. We have not authorized anyone to provide you with different information. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The date of this prospectus supplement is November 21, 2023. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLING SECURITYHOLDERS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This prospectus supplement is filed solely for the purpose of including selling securityholders who have acquired Common Stock included for resale in this Prospectus from certain previously identified selling securityholders named in the Prospectus whose shares were registered for resale in the Registration Statement. Where the name of a selling securityholder identified in the table below also appears in the table in the Prospectus (i.e., ARYA Sciences Holdings III), the information set forth in the table below regarding that selling securityholder supersedes and replaces the information regarding such selling securityholder in the Prospectus. Information regarding the selling securityholders listed in the table below, including the number of shares of Common Stock beneficially owned by them, is based on information provided by such selling securityholders as of the date of this prospectus supplement. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The percentage of beneficial ownership after the offered shares of Common Stock are sold is calculated based on 124,968,503 shares of Common Stock outstanding as of November 15, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information about the selling securityholders, including those listed below, may change over time. Since the effectiveness of the Registration Statement of which the Prospectus is a part, certain securityholders may have sold or otherwise transferred their securities registered thereunder. This prospectus supplement does not provide any updates with respect to any sales or transfers, except for those expressly disclosed in the table below. As of November 21, 2023, the Selling Securityholders table included under the section &#8220;Selling Securityholders,&#8221; which begins on page 12 of the Prospectus, is revised to amend the information solely with respect to the following selling securityholders&#58; </font></div><div><font><br></font></div><div style="padding-left:25.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.467%"><tr><td style="width:1.0%"></td><td style="width:38.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.588%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:60pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common <br>Stock <br>Beneficially <br>Owned <br>Prior to <br>Offering</font></td><td colspan="6" rowspan="2" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="18" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br>Shares of <br>Common <br>Stock <br>Being <br>Offered</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock <br>Beneficially <br>Owned After the <br>Offered Shares <br>of <br>Common Stock <br>are Sold</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Selling Securityholder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARYA Sciences Holdings III (1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Perceptive Life Sciences Master Fund, Ltd. (2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,428,351</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,731,313</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,038</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C2 Life Sciences LLC (3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,860</font></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,860</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Altman (4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,762</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,860</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,902</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other selling securityholders not previously named in the Prospectus (5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,580</font></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,580</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with and pursuant to a liquidating distribution by ARYA Sciences Holdings III (the &#8220;Sponsor&#8221;) on November 15, 2023 (the &#8220;Sponsor Distribution&#8221;), the Master Fund (as defined below) received 3,317,200 shares of Common Stock and Perceptive SP(B), L.P. (the &#8220;Co-Investment Fund&#8221;) received 829,300 shares of Common Stock. In connection with and pursuant to a distribution by the Co-Investment Fund of all of the shares of Common Stock it received in the Sponsor Distribution to the distributees identified herein.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Perceptive Advisors LLC (&#8220;Perceptive&#8221;) is the investment advisor to Perceptive Life Sciences Master Fund, Ltd (the &#8220;Master Fund&#8221;). Joseph Edelman is the managing member of Perceptive. Perceptive and Mr. Edelman may be deemed to beneficially own the shares held by the Master Fund.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Perceptive serves as the investment advisor to C2 Life Sciences LLC. Joseph Edelman is the managing member of Perceptive. &#160;Mr. Edelman may be deemed to beneficially own the shares held by C2 Life Sciences LLC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consists of (i) 165,860 shares held by Mr. Altman and (ii) 175,902 shares of Common Stock issuable upon exercise of options held by Mr. Altman. Options to purchase 150,980 shares of Common Stock are exercisable within 60 days of November 20, 2023. Of the remaining 24,922 options to purchase shares of Common Stock (i) 18,750 options to purchase shares of Common Stock vest evenly on the 15th day of each month through June 15, 2024, and (ii) 6,172 options to purchase shares of Common Stock vest evenly on the 9th day of each month through June 9, 2024, in each case, subject to Mr. Altman's continued status as a service provider through each vesting date. Mr. Altman is a member of the Board of Directors of the Company.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The aggregate holdings of such selling securityholders is less than 1% of the shares of Common Stock outstanding prior to the offering.  Certain of the selling securityholders were officers of ARYA Sciences Acquisition Corp III prior to the consummation of the Business Combination.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@   @<   "(" (   #\NM](     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  #L,   [# <=OJ&0  $3S241!
M5'A>[9T'0!3'WL#9JUP#[N#HO5<11$&LV+";:(P:33&QQ&?RI>>EO1?3R\M+
M>>E=8S2)O6%%Q5X01>F]=SC@X'K[_GN["@IWW,$=H)E?-KBSN[<[,SOS+],6
MT^ET-@@$ H% Z*&0_R(0" 0"@;0" H% (+J#M ("@4 @ND!: 8% (!!=(*V
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M&H^&S@:C8A2,0J51;.ET/L?6F<=VY;%<>&QW@5V04.#O:"=@VY+W&A[T7RL
MWL[\CQ=.&N'F!/M#J!L:.J4S_ONGTJCODO?V:G)O$ $#(>F3/V1*%1&<&!GP
MW>*D0<NH@L;6^[[:009Z8W*XW[=+IY$!2W.VK/:5G6DM8@D9[L'D"/__+IS$
MIM/(<&^ B/GU7-9_CEPBPT/*MG7W1^F+>I\<S:]Z9NMA,M ;4T-]OE@ZC4HQ
MVU.?_>WNLKIF,M ;*Z?$O3PYA@P,$8]L34W/+R,#/:!@V+.SQZZ.CR##EN;/
MJP7O'3AG2"L +\Y,>'QLY,"K(2AI^%O9UOG=^:SC-TKD2A7X!V:)4\@**I7"
MH%'#?=Q6)D3$>SO;4G$%,H1*G6! 8Y J&UN?_O/XP;P*C;FZQ<(,<2;V"I20
M[=>*%*JN3N;<BKH;=2UD &$2P_'-6H![-%E_'V0J55I)S8N[3B_X9M>>2[D=
M,H4*'X5CGA2$'ZC4&HE<F5Y0\8]-!V=]N7/#P0N'\\I;)/*A%:@#T@I 4UO'
M:SM/_G AVT@#CM496I5D@*9.:5I>.105,FQC(Y)(C^:6:;1#EU$(!&+ M,H4
M_TZY\.S68P>O%RH49$O P&EH[=AV*??E;2<6_K!G\]5\XXT?5F6@6@$ S^FG
MM&O_/9G1J5 ,B8JC8'A3 QD8'H 5<+JX)KNVJ;N?"NK@>%Y%<;.Q=F$$ C%L
M 9,NK;AZ^:\I!S(*E'@CE26=/KSE"+-1:[2-K1T?[#T[YYM=F]-SVV7RP1=N
M%M *@$RAW'SVQM,[3\E40]#/3J?1AK!7HR>0 U*EZF!.F4)YYQR%RN:V"Z5U
M9 "!0-P]@$KX*[/PY>TGR^I;!J$-L+JI;<^U(O!+!K^;P3): 8 LNYA?ON:/
M8X5-K?H&MN%EO \NNLR:IHN%E62H&Y QWY_-5*C1C#8$XNY"=RBO_,O4#+%4
M3AZP,@P:-3G"U].!!X\F#PT6%M,*>K"KI;7/;4_+!5TZ+-OZ!P>55O=FRGDR
MT(.V=NE_TJX-25,; H'H!U!;J]LZWSUPOJU3.FBM$FX"NP=B@FGX0+6[UE<@
M@.PK:VA9N^78J9(:M4;S]_08CA94U389[CS ;/:DY]=W2LD@HB\P,S&E$I&7
MF@/Y2\3?#[%"M>:/U';#DV]N <8>@TX/<!%,"?=[,"%RS=2XYV<GOC)__#.S
MQCZ>%+LH/GQ:A%^DI]"1QZ$9G:D#Y>T?27%\UM#,8QC0? 4C<%G,M4FQ#\>%
M,J@4#+.P[KF#-KERTL>_ZSM_##)H\Q7$<L6JS8>SJAK)<.]@CTR,_N?4.'QH
MLM6X%^8KZ+25K1WF]L^?S*O8F5% !GHC(=CKH;A0BIF3R$9[N]K9,LF 4?J>
MKQ#F\\42-%_!*EA\O@+>ZGLA^\LCE[1&1"6<P6Q T">/"'PL/MS%CL-G,?5F
M_IUHM+I.I:I=IFB5RHX75A_,+JUK:=-V&ZE(,"G"_ZO%2;W>81"PUE,[98JO
M4M._.Y<EQU_/W\5C@ *45E1=WMQ.A@VBNU)272'J\S($YB.PFQKL8]86Y-S'
M#&0/!VY2L-<=O^ISXS$9Y.\1?R<:.V5G\RN,J01<P.E\G06?+)GZX?QQ$:Z.
M0@[+D$ '(]G>EN'-YXWP$#XW.>;P/^[?O&K^ PF1(>Y.3 :=N,:>PWIFTDB:
MF5:+!;&B+E(H\1&KS^T^W:E0_DT40X="=:JPLD/6]]*!A?6MZ17UYCIJ?S?T
M!ITUZ@;<U^R2CQJ1_I[DU+<4-;62 0,X">R_6C9M1H@WC4(UL9S@PU QC$:E
MQG@(WYH5_]/#,[]_.'E*5""#09\?'>CG:&^=DF\2UO50U!K-J>S2?VP[6=+<
MKM5/$+^' 1&?6]^2FEM.AHT".;/Y<I[8<E-@$ B$Q0$7H;JEO</HN"-;.NU_
MBY,"'.W[-X04= ,%HSAQ6/$^;E\O3CKZ[(,KQT7!/<G30X%UM0+!E>+JYW>F
M%36UZ4UC*UC'5KJMF8 7N>ERGK+;$A?&*:UO.5E4C=P%!&+8HE1K;]2V&*^C
MXT*\0UWZ7C;11%RX;#<>APP,$8.A%4#P%=8T/;SI8'I5@UIC>2'(H$(JAMZ[
MSZT7I665D@$3T&IU'Q^]-(3SVA$(A'%46DUYJY@,&"#"U9%)'4K3WN(,AE8@
MZ.B0_=\?J7]<S;?X'*Y^C.6P-#JE6OW>P8LVF'DZK[6]\]=AL$PT H'H"9BS
M&JVVLZ]F7CZ+,?02R*(,:FK:);+_'+[T^^4\D*'W6,O)I<J&HGIC0P9[!?+@
MR(WBUL&:+8E ($P'[P[&*#U&C=[)D"SS8U4&6\>I5.K/CJ6_?N!\NWQHEM*S
M!A*E>L^U0NG-[RB8#H;9E#6U'<HMPWLE$ C$< (74#I=GR-$\QO;%$.X8K05
M& +/1Z/1',@H>&Y'6HVX\]Z0A=EU+9?+:@WI. H%,S)A2J%2G\RO;)8@=P&!
M&&9@^)R[/N>I',DIK6J]I[[*/D3M89C-I>+J%W>DE;6T$9\TNGM1:[3'"RJ:
MQ097L!CI[S'"RX4,],:ETIK"!M'=G@\(Q#T&9H,Q:-0@H0,9-H!"H7IQQ\FJ
MMHY[9H$?"VL%*I7B:,^A&UWB@P"\L^L5]8N^WW>]MD6MO8O'X8BD\JV&O]1/
MI6 ;9B7$>KL8F=JB4FL^3+V"FI 0B.$&:(61'L(^%T<IK&U>N_EP?H-(<T_8
M=A;6"C0J=>7XZ%?G)-(9)@W5DLL5_]AR=.^-$J7F;NRQ@2CK/CJ1H3&\Z,JD
MR(! (7]^=) 3ET4>ZHV2VN83Q35DX![GUENVUNMVX+"#/(1!'DXAGLY1OFX]
M-V^!G?6>CI<*N#G<7O\$O(CHT9]"W&6 -O 4\)SL^IA 0'00/K7UV)>GK[?+
MB![3N_B-6U@K0';0,&QI;/ ?J^;9<]GZ7.V#UD[IFWO/[KY>K+[[U"Q6U-QV
M,"//4)5G,.@?S1L'61 L= CS=B./]H96J_WDV*7NG_.\VZ%@&)-&8S/H7%N&
M'=O6@<,2\-A"/L_=F>_CYNCO(?03\JG664-BP8B ?6OOV[OFOMVKYV][?&[/
M;?782.NM,0.%P5O FQX;,C;"=T2@1Z"7B[>KDYLCW\F!R^>Q[3FV'%L&Y(PI
M50,Q'(CU%$9[.I,!H]2V=GR7>F7:YW_MS2[M5*CNWLILX353Z73:\\GQCXT)
MA]MFUC2^>_!B;K7QU4-)*!3*@V/"GIH<(V#;FCMQ7*71Q+V[46ET&( UUDQ5
M:C1O[#NW_YJ!Y3EU-O>/#GU[3B+X3Y ;Y:WB.5]LUVIUAB0ADT[[UX+Q"T<$
M]F_>?$^&=LW4=KFB5BRUI5&Y#!J#2J53*;#1P!6WCB88_L"K5VDU2K56KM%
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MM" /G0[N;+:CBB" %T14,3 H-*!@X>_MF][0L%:)(NY\LY);ZRG#&>OE[7
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M4&^D$*P-T@K] 6IXC']7UW&?C3"&@,H@EBNW7LX#^Q&"8,>MFS+JX_GCN[7
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M>+I$A.'1Y\IJ+Q97$:?\7!U?F1I'Q>!E]9*E" N"M(+9@'16:;45+:U$&ZC
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M,(P2["*8&>%'!*]6->36D4ITX$!!S:EON34D86*(3Y2'$ H/$30,MC0F1.C
MP_<PFWU7"SIZ**I]-XK)/1N;-V?&&QF9;3KOS$GDZ]LAX:'G"RK/E=9"_"^5
MUZ?EX5T=D*6C?-VFA_I2]1WU"&N#M$+?J#7:K9=SG]QV_,EM)U;]F9K\S<Z?
MT_!QUAPFX\DI<3-#?$RH;+T#4O)$8;5^5\=A,/0=VGW?"MSV\8$>M\:M@Y>M
MP3OKK )4SKH6\?T_'S"TO9)R'JXAK^X&Q*BNI0UN /M4*G6,MRMQ?,#HKI75
MWA&'[MN#&U-V7.\26Z8 ZNK%*:/638UCTNF0%I5:?>A:P<HM1YLZ<2O51-1:
MK5)OE4-9\',7<IE,4\H$ET'W%M@3Y:=%+&T2F_'$/FF7*EHE<F+?E\\SU,AS
M!VP&/=1#2.RK5)H&O:G>G;:;D10X<#SQ]L"! LGWYO/638BFZ16SJ%.^_WI1
MG5CRUL'SQ(@I%I.^/BF&S[8UI78@!@[2"GVCU>J*:YI.99>>RBXYGU=>W]P.
ML@.CV/B["F:&>^ME8K^%LJZR&1_+!/=@,FD.K#X<A5LXL!B,F[W$Y:*.WL2R
M98 :JU2I\ROJ#&T%#2V]*D4M. LW8X7AYJ2EHHAU2N5WQ.'VK5YT<YB6B6AM
M\'F":Q.COE@VU5W?W0I/R2BI?GK[B<I6R%N38MXB59 7ZFPF!GN:+KW UB8R
M$/[OAX-B!'S^LOZ&& 5C,^FF&]JCO5WP$JE'=OL0585: ^6!V/=V=.CI_$%V
MG2RNV955>L=V,*^\54:JJ)Y %DP/\QWI[0(_U]GHCN66/[WMA*B->(^ZM5/B
MHMU)1848!)!6, TH_B3D :C\617URWY..5%4!78B>=!L,*(A"&Z+UP>3)6=W
MWX!AN"O/(D#<:%2JP<W4!@1315*?P#NX,PZW;R!FR4M-0](AAQ^ 8)H8X/'Y
MDJE![DX0!%/@>EG=XA_WX:.\3'@O\!.B<(!0$\L5Q$%3N#5"7[]C<@DP"3(?
M0#]K<'?2U)M+56KB4@S3X:^_&^IN??&&LN6_)S)>WW[\CNW]_6?UDT(,XL)C
M/S@FG$[#AZ6JU9K<*K+M*\+';4U"!+P=(H@8!)!6Z!L:E3)G9/"&^>-A^_>\
M\2\DQT^+"J!2J5 KI%+Y<W\=WWF='$[>#\+=G?3_8C*%JA"? V%2U2T7B<4W
M9P"$NPG,E8/FH'.RYWVZ=)JA[:6D4;UJ,ZC&L!%GM""2+-7SH;,)\W*^(P[=
MMX\73YD:1K;4FPS$$L] B'*4F^/GBY/B@KP(F2?NE"[_.65/5G&? Y.$7%M"
M<H%N.)5;WM?E7>#R6G\U_)PQ@&[;GD"I(*:G 1*%2JTQ)4ZX;7*^I(80PA O
M>]O;_%<V@W9K0%%)?4O/IDM<-?9>&.%H[R<(X(>S0WUGQP2381R=@,=^+BG6
M$CT7"#- ^=TW4%U'^;H]."H4MJ5Q8:O&C?AR<=+&E7/LN?C@>I5*O?]:86.G
MA+C8+,!\FQ;D20@%J+?[LDMZU+)> -?D;&$5T08--3_1U\UD@[T?X$LP30_Q
M-K2-\7'MU8P#BSW2UXUHM=!J-']F]E]Q=@>RQY''N2,.W;=I(=Y^^'(Z_01$
MFK^CP\85,^Z+CR!F<K1+9&_M.[,CL]"XH(=TLO4-@/ V6\32NHZ^RP-<62^6
M7BBM(PJ CS,^B9TX-7! R+H[\#SY1(.837I58T-'9Y^Z#6B1RLOK6^ &$"N.
M+</-[K9A/_"N>5QR%F2G1'ZCKHF(_"T@Z&[/\72T)S:';A-0C.D$/5!8WIT[
MUD5 OCX*1ID5X1^'S]/L\Z<(2X*T@@GT4B:Q<%?!K)NC1\ U+FIJ)_;- JIN
MI)N3T!X?\J'1:M/R*O(;1'=4LSN L\5-;4=P:Q2_#.2(U\U:-'3T7FD7C0@@
M!ZA@V-8+-_)-]H2,T*L&LCA@![PQ8_2ZJ7%<W%+6*93J=_>?ZSFEZW:P9Z;B
M$YXAANTRQ1<G,CKQ%6$-IE=_2K<_N^1J11V1*U'N@D G4HA;!+A;C+<S;KS;
MV.16-VS-*#2>>1 E2.-W9ZZW2O#QM9"459-B>DYRG#,BD-S#;%[=?;I%*NN>
M3'C<UXLF'UB_*$6_/6EXP:B>0$S!OGEH=!@1=.#8SAH1R$3K'0TZ2"L,@)N5
M#&J%44EN$+!, YP<YD3Z$5477/(W4\X;Z92#AXAD\N=WGR+ZJ,%1F!SB$^XR
M3!>/=&3;+DHDUQ95JS3/_'&T66)LP9]^9:&5P#@,QI/C1KPT9RQ+OZ*J?C",
ML0C"N41_#P_<V,>M[/V9A3NO%1B>]Z #AR^MI.:S(Y?P6<<V-O8LVT?&15NV
MBXA&P9:-#K,C/1B;7],R-V?D$U,!>D6MTQW(+MN>GJ>/D8VW,S\YS/?.]B"=
MS?+88"<!;L< Y0VM;^P_URJ][;72J50FC<K0;Q '\JA)0#7 ;HV5 I."8W2)
M+8250%K!;*#.@UV?6EBE7]L #[K9<;QN3E(U%P:-LF1,6+"[$.HMZ(;LBOJE
M/QWX\VI^NQQ?(X^\"'^*5BQ7;+]6L.SGE+*;JV1'^[JO2HS4*Y1ARJM)H^(#
M/(G]JA;QZLV']V85JS7X&MK$00#V03)>K*C_]LSUFO;^-,19"7@=BT<$?OOP
MS!"R[\<8X%[X">R>GSK*'A] B7?P?GSHTBM[3D&Z[AA9!.DM%W5\E)K^W)^I
M1#[ @YZ>,3K"\"I,_04+=^$_GQQ/(>Q]3/>?E/.O[3V35=?<?8(+GO\Z;5Z#
MZ)V#%]XY< X?8J2S 5VR?M)('_Z=;BA$E8)1WI\_@:M/)I2],_F5Z_],_>-J
M ;[&W^VW!21]K;*'&(:@U?$,<FMU/!J5,C,V9*RO&^QKM+K*UH[4_/+RK@\8
M8$L3(]^<F4"&NF'Z2MKU'9+YW^SJN#FZ'.PSOATG*<QO:I"7$\>V12H_65)S
M(J>LI8T<Q0&UT<]=N&?57'W77Q]JX4QIW9J-!XC]DR\M=^7U/4&T^^IX=ES6
M Z.-?4Z 2L5FA7B%N3B2X=LI:!2]L".MI*[E5C3Y]KQ940$3 ]Q=>;:M,N6%
MBH9#V255]2*0.)\\D#0STI_HMNV.55?'\Q'8'WIF,3R=.'X'.AM=68OXU=VG
MKE?4$]<87TG[I\NY7QRZ0+QT@$JE!+@+9T<%Q'LY@^&<W]1V,+<LO:@*G"?B
M AJ%\NK<<<M&A1B*0+?5\70/)D9SC4T[T#T]8<3MBU'C2=R:4?A1RCF5?K(D
M0*%00KQ<YD;YCW1WHE,IV?4M*3EE-\KJB$4LX'H:%7MNUMC'QX0;BA+HN3\R
M"CXY<DG13>BS;!D1/JZCO%V\[+ERM::HJ?5267U%73.1R8Y<]M<KDJ--T*]_
M7,E_>]\9V!':<7YX=':HT&)]+0@305K!(,:_KT  U69:9,"_9B<(>UO6S8SO
M*]CH:ML[/SMQ]7A.J5RA-BCG]:,+.;:,!:-"UHV/%N+]?H8N[6* 6J%/:#3J
M>_=/FA\50(9O!PI8?E/KMZ<RCV65P'YW08-!\<,3A$,40W]7P>ZU"WHV)5M5
M*_@ZVA_\/X-: 8!(5K5U_N_XU93KA1#LX_L*-KIC!=7?IV7DUC3AH=M>$.R3
MZ<43C&$>C@[/3!DU(\R' 9*8/'$GW==,-0[<\N)KC]PQZP6>IU"KC^95_.]D
M1DVSL=XO_=NAA'L(UTX>.2W8"WP"\D0/((TJM?9(?OG7IS(K\)XPW$PQCAN?
M]\/#LTSI.$%:8<A!+4C]!.Q9@1WWG863OWA@DI/>FQX((!\]['D?+1C_U8J9
M3@([0U6,0L&"O)VWKIGWK^0Q0GP$5%]U<1@ TC94R/_B@<G?/S;;RX7?/<;=
M5(*.@MFX"NS6)<58<CR5Z=EC5*K!VP'[]^.%$]8DC3*B/ C@XADA7IM6SEH[
M?33CSN_*D>F%0W0&?652;,KZ^^=%^3,-JP0SZ>4V< B\AWF1?@?6+5PY.89!
MIT$,R7.W [%=-WWTIL=FS0CQ,:(2 +@#@T:9&^%_8-U]S\X<:\]C&<H6.,Z@
MTV?'A6Y=-4__J37$70#R%7I'I]/F-[:F9)'KUG6AT]%I5 <.*]#9(<+%T9[%
M,%3'@(K6CIT9>5K]!?-'! 2;]DU!L'9OU#9?KVZL%HG;90JU5D>G8GPVT\N)
M'^OE'.K,-U=NEHG$$ T;J.<ZW=J)!I>W[(Y&J_WLQ)5>I4Q/J!0L.<PWW,UX
MXP 4,TRB5.74BS*K&AK;.]OE2J5&"RFQLV6X.G"CO5RBW9TX>-<N?B7YHYO(
MU>JO3E[5RVZ=O[-@X:UA,#U0:S7G2VLOE^,?:?%PX,Z-"NB97J+,?WK\"E'T
M^2SFXXE1?8I[ .*_XUJA0JM;,S:2/&08>$JS5)91U5A0U](HEL)OX0$L.LV)
MQPYV%8SR<G;E<4QXJ&YO5DE10RL9,H(^4>LGQ\(CB ,]@2C5=TBO5#44U;<T
M=\CPV6HZ&RZ3)K1CA[HYC?9V=33?OH%[BJ3RK/KFO#I14WMGAT*I4.MH% Q>
MJ[,])]3-,<+5T9EC4&WT)+.Z,57_15(N@[XH-D1O_2 &%:05#$%D2\^BC.<7
M: *P<XWH X+;K]'_SAS@!\3;P7]F>JVR#(:2WRMF70Q JKH*'F21/FT0'-PD
M=F%J_/7.#297:U@F33?K2A$D]M8S(+7Z@D&$3,'$G"%+)ADR!G[AK;D+1)2(
M_0& WQ//'^(__)8#N2EQ-WS'M!0A+ G2"@@$ H'H O4K(! (!*(+I!40" 0"
MT072"@@$ H'H FD%! *!0'2!M ("@4 @ND!: 8% (!!=(*V 0" 0B"Z05D @
<$ C$36QL_A]607WXJE&[Q0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
